RE: RNS31 Aug 2023 17:35
It's just in previous RNS'. The amount he is quoted as holding on 25 August (6,603,082) is the same as the holdings RNS released on 31 October 2022.
I'm not in touch with any brokers but the last update in the results RNS was optimistic of all being on track with the following comment:
"We are delivering on these plans at pace, with an anticipation that is clearly shared by the many physicians who have already requested the PSE test for their patients. With several US-based laboratory staff already recruited, we remain on track to complete equipment installation, technology transfer and test validation in time for the planned launch in Q4 2023."
There was also an interesting snippet on the use of EpiSwitch in relation to what we know as MND in the UK which the market is sleeping on.
I don't offer advice when I say this but OBD represents, in my view, one of AIMs home runs. Commercialisation is the challenge and progress is often steadier than the market would like, but on what we know this should be on every watchlist in advance of Q4.